Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Avidity Biosciences, Inc. (RNA) Assets Average (2020 - 2025)

Avidity Biosciences' Assets Average history spans 6 years, with the latest figure at $2.0 billion for Q4 2025.

  • For Q4 2025, Assets Average rose 27.7% year-over-year to $2.0 billion; the TTM value through Dec 2025 reached $2.0 billion, up 27.7%, while the annual FY2025 figure was $1.8 billion, 60.64% up from the prior year.
  • Assets Average reached $2.0 billion in Q4 2025 per RNA's latest filing, up from $1.8 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $2.0 billion in Q4 2025 to a low of $302.6 million in Q2 2021.
  • Average Assets Average over 5 years is $870.4 million, with a median of $606.6 million recorded in 2023.
  • Peak YoY movement for Assets Average: increased 2.13% in 2021, then skyrocketed 166.67% in 2024.
  • A 5-year view of Assets Average shows it stood at $426.7 million in 2021, then rose by 25.29% to $534.7 million in 2022, then rose by 12.38% to $600.9 million in 2023, then surged by 166.67% to $1.6 billion in 2024, then rose by 27.7% to $2.0 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Assets Average are $2.0 billion (Q4 2025), $1.8 billion (Q3 2025), and $1.4 billion (Q2 2025).